- Home
- QTTB vs ALGS Comparison
QTTB vs ALGS Comparison
Compare QTTB & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | QTTB | ALGS |
|---|---|---|
| Founded | 2015 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.3M | 43.0M |
| IPO Year | 2018 | 2020 |
Fundamental Metrics
Financial Performance| Metric | QTTB | ALGS |
|---|---|---|
| Price | $6.82 | $7.57 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $13.00 | ★ $46.67 |
| AVG Volume (30 Days) | ★ 177.3K | 31.7K |
| Earning Date | 06-22-2026 | 06-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 136.78 | 88.30 |
| EPS | ★ 2.42 | N/A |
| Revenue | ★ $53,737,000.00 | $2,186,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $2.91 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.38 | $3.76 |
| 52 Week High | $7.65 | $13.69 |
Technical Indicators
Market Signals| Indicator | QTTB | ALGS |
|---|---|---|
| Relative Strength Index (RSI) | 76.03 | 56.23 |
| Support Level | $3.75 | $7.61 |
| Resistance Level | N/A | $8.84 |
| Average True Range (ATR) | 0.60 | 0.55 |
| MACD | 0.24 | 0.15 |
| Stochastic Oscillator | 73.55 | 85.21 |
Price Performance
Historical ComparisonAbout QTTB Q32 Bio Inc.
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function.
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.